Revision of Prior Period [Axis] Revision of Prior Period [Axis] Subsequent Events [Table] Subsequent Events [Table] Subsequent Events [Table] Deferred tax assets Deferred tax assets Janssen Biotech, Inc. Janssen Biotech, Inc. [Member] Janssen Biotech, Inc. Summary of Financial impact of IFRS 16 adoption Financial impact of IFRS 16 adoption [Text Block] Financial impact of IFRS 16 adoption Significant Subsidiary Plan Gelesis 2016 Plan - Range of assumptions of Fair Value of stock option grants Significant Subsidiary Plan Gelesis 2016 Plan - Range of assumptions of Fair Value of stock option grants [Text Block] Significant Subsidiary Plan - Gelesis 2016 Plan - Range of assumptions of Fair Value of stock option grants Subsidiary Notes Payable Subsidiary Notes Payable [Member] Subsidiary Notes Payable Kiran Mazumdar-Shaw Kiran Mazumdar-Shaw [Member] Kiran Mazumdar-Shaw Functional and Presentation Currency Description of accounting policy for functional currency [text block] Percent, number of shares held Percent, number of shares held Percent, number of shares held Restricted Share Units Restricted Share Units (RSU) [Member] Restricted Share Units (RSU) [Member] Subsidiary operating companies Subsidiary operating companies [Abstract] Subsidiary operating companies Sensitivity Range Percentage of reasonably possible increase in unobservable input, assets Income Tax Type [Axis] Income Tax Type [Axis] Income Tax Type Cash Distribution Cash Distribution Cash Distribution 0.01 Exercise Price Range One [Member] Exercise Price Range One [Member] Disclosure of Subsidiary Preferred Share balances Summary of Subsidiary Preferred Shares Balances [Text Block] Summary of Subsidiary Preferred Shares Balances Statistical Measurement [Domain] Statistical Measurement [Domain] Disclosure of Maturity Analysis of Operating Lease Payments [Table] Disclosure of maturity analysis of operating lease payments [table] Classes of financial liabilities [axis] Classes of financial liabilities [axis] Executive Compensation Executive compensation, reconciliation of effective tax rate Executive compensation, reconciliation of effective tax rate Security Exchange Name Security Exchange Name Mark to Market Adjustments Mark to Market Adjustments Mark to Market Adjustments Disclosure Of future payments Of Finance Lease Payments Receivable Explanatory Disclosure Of future payments Of Finance Lease Payments Receivable Explanatory [Text Block] Disclosure Of future payments Of Finance Lease Payments Receivable Explanatory Common Shares, value realised assigned to PureTech Health, LLC [Member] Ordinary Shares, value realised assigned to PureTech Health, LLC [Member] Ordinary Shares, value realised assigned to PureTech Health, LLC Associates Description of accounting policy for investment in associates [text block] Within Three Months Within Three Months [Member] Within Three Months Non-Controlled Founded Entities Non-Controlled Founded Entities [Member] Non-Controlled Founded Entities Issued ordinary shares at January 1, Number of shares outstanding Purchases of intangible assets Purchase of intangible assets, classified as investing activities Number of warrant, in percentage of converted shares Number of warrant, percentage of converted shares Number of warrant, percentage of converted shares Investment, Name [Axis] Investment, Name [Axis] Non-adjusting events after reporting period [member] Non-adjusting events after reporting period [member] Minimum liquidation preference Minimum liquidation preference Minimum liquidation preference Share premium Share premium Equity and liabilities Equity and liabilities [abstract] Final fee, percentage of original principal amount outstanding Debt instrument, payment terms, final fee, percentage of original principal amount outstanding Debt instrument, payment terms, final fee, percentage of original principal amount outstanding Weighted average grant date fair value, RSU vested (in GBP per share) Weighted average grant date fair value of other equity instruments Vested in share-based payment arrangement Weighted average grant date fair value of other equity instruments Vested in share-based payment arrangement Disclosure Of Total Operating Expense Disclosure Of Total Operating Expense Explanatory [Text Block] Disclosure Of Total Operating Expense Explanatory Subsequent Events [Line Items] Subsequent Events [Line Items] Subsequent Events Disclosure of share capital, reserves and other equity interest [Abstract] Disclosure of share capital, reserves and other equity interest [Abstract] Operating Expense [Member] Operating Expense [Member] Operating Expense Lease liabilities Balance at beginning of period Balance at end of period Lease liabilities Estimated fair value of the convertible preferred shares Estimated fair value of the convertible preferred shares, measurement input [Member] Estimated fair value of the convertible preferred shares, measurement input Disclosure of detailed information about intangible assets Disclosure of detailed information about intangible assets [text block] Share Capital Description of accounting policy for issued capital [text block] Share-based payment expense Share-based payments Expense from share-based payment transactions with employees Disclosure of gain on deconsolidation Disclosure of gain on deconsolidation [Text Block] Disclosure of gain on deconsolidation Entity Address, Country Entity Address, Country General And Administrative [Member] General And Administrative [Member] General And Administrative Mark-to-market adjustments Rate of Mark to Market Adjustments Rate of Mark to Market Adjustments Key Management Personnel Compensation Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block] Disclosure of detailed information about property, plant and equipment Disclosure of detailed information about property, plant and equipment [text block] Equity - Acquired Share capital PureTech LLC [Line Items] Equity - Acquired Share capital PureTech LLC [Line Items] Equity - Acquired Share capital PureTech LLC Impairment of investment in associate Impairment loss recognised in profit or loss Ensof Holdings, LLC (held indirectly through Enlight) Ensof Holdings LLC [Member] Ensof Holdings LLC Issuance of long term loan Proceeds from non-current borrowings 2018 Performance Based RSU [Member] 2018 Performance Based RSU [Member] 2018 Performance Based RSU Other Financial Assets [Abstract] Other Financial Assets [Abstract] Weighted Average Options exercisable [Table] Weighted Average Options exercisable [Table] Weighted Average Options exercisable [Table] Unrealized gain/(loss) on investments held at fair value Unrealized gain on investments Other comprehensive income, before tax, gains (losses) from investments in equity instruments Foreign Currency Description of accounting policy for foreign currency translation [text block] Depreciation of tangible assets Depreciation expense Depreciation expense Subleases Income from subleasing right-of-use assets Fair Value Measurements Description of accounting policy for fair value measurement [text block] Number of shares issuable based on performance conditions Number of shares issuable based on performance conditions Number of shares issuable based on performance conditions Directors and Senior Managers Directors and Senior Managers [Member] Directors and Senior Managers Disclosure of performance obligations [text block] Disclosure of performance obligations [text block] Purchase of investments held at fair value Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities Increase Decrease In Number Of Shares Outstanding, Changes In Ownership Interest In Subsidiaries That Do Not Result In Loss Of Control Increase Decrease In Number Of Shares Outstanding, Changes In Ownership Interest In Subsidiaries That Do Not Result In Loss Of Control Increase Decrease In Number Of Shares Outstanding, Changes In Ownership Interest In Subsidiaries That Do Not Result In Loss Of Control Document and Entity Information [Table] Document Information [Table] Reconciliation of changes in fair value measurement, assets [abstract] Reconciliation of changes in fair value measurement, assets [abstract] Weighted-average statutory rate Applicable tax rate Other Other, non-controlling interest, equity Other, non-controlling interest, equity Licences [member] Licences [member] Additions Additions other than through business combinations, intangible assets other than goodwill Gelesis, Inc. Gelesis [Member] Gelesis [Member] Gelesis Deferred tax assets Deferred tax assets [Member] Deferred tax assets Changes in the value of subsidiary preferred shares [Line Items] Changes in the value of subsidiary preferred shares [Line Items] Changes in the value of subsidiary preferred shares Interest Expense Rate of interest expense, reconciliation of effective tax rate Rate of interest expense, reconciliation of effective tax rate Disclosure of changes in financial liabilities - Warrants Disclosure of financial liabilities - Warrants [Table Text Block] Disclosure of financial liabilities - Warrants Minimum liquidation preference [Line Items] Minimum liquidation preference [Line Items] Minimum liquidation preference Disclosure of short-term and long-term portion of lease receivable Disclosure of short-term and long-term portion of lease receivable [Text Block] Disclosure of short-term and long-term portion of lease receivable Statistical Measurement [Axis] Statistical Measurement [Axis] Non-cash items: Non-cash items [Abstract] Non-cash items Equity Instruments Issued by the Group Description of accounting policy for equity instruments issued by the group [Policy Text Block] Description of accounting policy for equity instruments issued by the group Purchase of convertible note Cash purchase of convertible notes Purchases of Convertible Note Purchases of Convertible Note Series A-2 Preferred [Member] Series A-2 Preferred [Member] Series A-2 Preferred [Member] Capital And Financial Risk Management Credit Risk [Abstract] Capital And Financial Risk Management [Abstract] Investments in associates As of As of Investments in associates Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Distribution to shareholders on dissolution of subsidiary Distribution to shareholders on dissolution of subsidiary Distribution to shareholders on dissolution of subsidiary Lease receivable – short-term Short-term Portion of Lease Receivable Current finance lease receivables Income/(Loss) for the year Net income/(loss) Income/(loss) for the year Profit (loss) Long-term loan Non-current portion of non-current borrowings Aggregate payroll costs Total Payroll Costs Payroll Costs Payroll Costs Disclosure of performance obligations [table] Disclosure of performance obligations [table] Amendment Flag Amendment Flag Disclosure of accumulated depreciation and impairment loss Disclosure of accumulated depreciation and impairment loss [Text Block] Disclosure of accumulated depreciation and impairment loss Gain/(Loss) on derecognised sale of asset Gain/(Loss) on derecognised sale of asset Gain/(Loss) on derecognised sale of asset Recognition of deferred tax assets not previously recognized Deferred tax assets not previously recognised Deferred tax assets not previously recognised Floating interest rate [member] Floating interest rate [member] Segment Information [Abstract] Segment Information [Abstract] Segments [axis] Segments [axis] Accounting Policies - Subsidiaries [Table] Accounting Policies - Subsidiaries [Table] Accounting Policies - Subsidiaries Owners of the Company Income/(loss) for the year, attributable to the owners of the Company Profit (loss), attributable to owners of parent Geographical areas [axis] Geographical areas [axis] Disclosure of maturity analysis of finance lease payments receivable Disclosure of maturity analysis of finance lease payments receivable [text block] Gain on investment at initial public offering Gain on investment at initial public offering Gain on investment at initial public offering Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract] Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract] Recurring fair value measurement [member] Recurring fair value measurement [member] Other Other current payables Settlement of RSU's Settlement of RSU's Settlement of RSU's Disclosure of Reconciliation of Effective Tax Rate Disclosure of Reconciliation of Effective Tax Rate [Text Block] Disclosure of Reconciliation of Effective Tax Rate Financial Instruments - Warrants [Abstract] Financial Instruments - Warrants [Abstract] Financial Instruments - Warrants Financial assets, class [member] Financial assets, class [member] Income/(loss) attributable to: Profit (loss), attributable to [abstract] Interest paid Borrowings, Interest paid Borrowings, Interest paid Commense Inc. Commense Commense [Member] Commense Recognised Income Tax Expense [Line Items] Recognised Income Tax Expense [Line Items] Recognised Income Tax Expense Reclassifications Increase (decrease) through transfers from construction in progress, property, plant and equipment Gain/(loss) on investments held at fair value Gain/(Loss) on changes in fair value Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, assets Subsidiary Operating Companies [Member] Subsidiary Operating Companies [Member] Subsidiary Operating Companies Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Receipt of PPP loan Proceeds from current borrowings Subsidiary Convertible Notes Subsidiary Convertible Notes [Member] Subsidiary Convertible Notes Payables to related parties Payables to related parties Total assets Total assets Assets Disclosure of detailed information about property, plant and equipment [abstract] Accumulated deficit Accumulated Deficit Accumulated Deficit Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [text block] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [text block] Amortization of intangible assets Amortisation expense Amortisation expense Dr Raju Kucherlapati Dr Raju Kucherlapati [Member] Dr Raju Kucherlapati One year to Five Years Later than one year and not later than five years [member] Deconsolidation of subsidiary Deconsolidation Deconsolidation Deconsolidation Deconsolidation Interest expense on lease liability Interest expense Disclosure of Property & Equipment, net Schedule of Property & Equipment net [Text Block] Schedule of Property & Equipment net Other Other tax rate effects for reconciliation between accounting profit and tax expense (income) Interest expense Interest expense on lease liabilities Effects of state tax rate in U.S. Rate of Effects of state tax rate in US Rate of Effects of state tax rate in US Disposals Disposals, property, plant and equipment Disclosure of Weighted-Average Number of Ordinary Shares Weighted-Average Number of Ordinary Shares [Text Block] Weighted-Average Number of Ordinary Shares Total non-current liabilities Non-current liabilities Non-current liabilities Disclosure of disaggregation of revenue from contracts with customers Disclosure of disaggregation of revenue from contracts with customers [text block] Subsequent Events [Abstract] Subsequent Events [Abstract] Deconsolidated former subsidiary operating companies Deconsolidated former subsidiaries [Abstract] Deconsolidated former subsidiaries Disclosure of Earnings/(Loss) attributable to owners of company Earnings Loss attributable to owners of company [Text Block] Earnings Loss attributable to owners of company Prepaid expenses Current prepaid expenses Group's share of net assets Share of net assets Share of net assets Significant Subsidiary Plan -Vedanta 2010 Plan - Range of assumptions of Fair Value of stock option grants Significant Subsidiary Plan -Vedanta 2010 Plan - Range of assumptions of Fair Value of stock option grants [Text Block] Significant Subsidiary Plan - Vedanta - Range of assumptions of Fair Value of stock option grants Proportion of ownership interest in subsidiary Proportion of ownership interest in subsidiary Interest from financial assets not at fair value through profit or loss Interest income for financial assets not at fair value through profit or loss Trade and other payables [abstract] Option pricing model [member] Option pricing model [member] Loss realized on sale of investments Losses on disposals of investments Inactive subsidiaries Inactive subsidiaries [Abstract] Inactive subsidiaries Entity's total for segment consolidation items [member] Entity's total for segment consolidation items [member] Finance Cost, net Disclosure of finance cost [text block] Other income/(expense) Other income/(expense) Other gains (losses) Share-based payment arrangement, amount withheld for tax withholding obligation Share-based Payment Arrangement, Amount Withheld for Tax Withholding Obligation Share-based Payment Arrangement, Amount Withheld for Tax Withholding Obligation Income/(loss) before taxes pre IFRS 9 fair value accounting, finance costs – subsidiary preferred shares, share-based payment expense, depreciation of tangible assets and amortization of intangible assets Profit Loss Before Tax pre IFRS 9 Profit Loss Before Tax pre IFRS 9 Gain/(loss) on investments held at fair value Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Less than 1 Year Contract Duration Less Than One Year [Member] Contract Duration Less Than One Year [Member] Imbrium Therapeutics L.P. Imbrium Therapeutics L.P. [Member] Imbrium Therapeutics L.P. Long-term loan Beginning balance Ending balance Borrowings Valuation techniques [member] Valuation techniques [member] Summary of Investments in Associates Summary of Investments in Associates [Text Block] Summary of Investments in Associates Retained earnings/ (accumulated deficit) [member] Retained earnings [member] Number of Options held Number of Options held Number of Options held Weighted Average Warrants Significant unobservable input, liabilities Subsidiary Preferred Shares [Abstract] Subsidiary Preferred Shares [Abstract] Subsidiary Preferred Shares [Abstract] Share-based Payments Table [Line Items] Share-based Payments Table [Line Items] Share-based Payments Table Warrant liability Current derivative financial liabilities Risk free interest rate Risk Free Interest Rate, measurement input [Member] Risk Free Interest Rate, measurement input Income of partnerships not subject to tax Tax rate effect of revenues exempt from taxation Exercise Price Range Exercise price of outstanding share options Assets Assets [abstract] Subsidiary Preferred Shares Subsidiary Preferred Shares [Member] Subsidiary Preferred Shares Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Construction in progress [member] Construction in progress [member] Schedule of Convertible Notes Schedule of Convertible Notes [Text Block] Schedule of Convertible Notes Exercise of share-based awards Effect of shares issued Increase (decrease) in number of ordinary shares issued Other reserve Other reserves Conversion of subsidiary convertible note into subsidiary common stock (NCI) Conversion of subsidiary Convertible note into subsidiary common stock Conversion of subsidiary Convertible note into subsidiary common stock Conversion of subsidiary convertible note into preferred share liabilities Conversion of subsidiary Convertible note into preferred share liabilities Conversion of subsidiary Convertible note into preferred share liabilities Sale of asset, paid at closing Sale of asset, paid at closing Sale of asset, paid at closing Operating Segments Description of accounting policy for segment reporting [text block] Weighted average stock price of share options exercised in share-based payment arrangement Weighted average stock price of share options exercised in share-based payment arrangement Weighted average stock price of share options exercised in share-based payment arrangement Controlled Founded Entities Controlled Founded Entities [Member] Controlled Founded Entities Changes in the value of subsidiary preferred shares [Table] Changes in the value of subsidiary preferred shares [Table] Changes in the value of subsidiary preferred shares [Table] Share based Payment Measurement Share based Payment Measurement Share based Payment Measurement Disclosure of liquidity risk Disclosure of liquidity risk [text block] Amortization of ROU assets Depreciation Depreciation, right-of-use assets Increase (decrease) through conversion of convertible instruments, equity Increase (decrease) through conversion of convertible instruments, equity Weighted Average Options forfeited [Line Items] Weighted Average Options forfeited [Line Items] Weighted Average Options forfeited Disclosure of stock option activity Disclosure of number and weighted average exercise prices of share options [text block] Finance income/(costs) – contractual Total finance income/(costs) Finance costs Finance costs Lighthouse Capital Partners VI, L.P Lighthouse Capital Partners VI, L.P [Member] Lighthouse Capital Partners VI, L.P Vested (in shares) Number of other equity instruments exercised or vested in share-based payment arrangement Disclosure of revenue from contracts with customers Disclosure of revenue from contracts with customers [text block] Subsidiary Preferred Shares Disclosure of Subsidiary Preferred Shares [Text Block] Disclosure of Subsidiary Preferred Shares Non-Controlling Interests [Abstract] Non-Controlling Interests [Abstract] Non-Controlling Interests [Abstract] Disclosure of significant unobservable inputs used in fair value measurement of assets [line items] Disclosure of significant unobservable inputs used in fair value measurement of assets [line items] Owners of the Company Comprehensive income, attributable to owners of parent Reclassification of investment at initial public offering Reclassification of investment at initial public offering Reclassification of investment at initial public offering Investment upon deconsolidation Investment upon deconsolidation Investment upon deconsolidation Dr Robert Langer [Member] Dr Robert Langer [Member] Dr Robert Langer Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Subsidiary Preferred Shares [Table] Subsidiary Preferred Shares [Table] Subsidiary Preferred Shares [Table] Equity - Acquired Share capital PureTech LLC [Table] Equity - Acquired Share capital PureTech LLC [Table] Equity - Acquired Share capital PureTech LLC [Table] Weighted Average Options Outstanding [Abstract] Weighted Average Options Outstanding [Abstract] Weighted Average Options Outstanding (Gain)/loss on investments held at fair value Adjustments for fair value losses (gains) Other selling, general and administrative expenses Other Selling General and Administrative Expense Other Selling General and Administrative Expense Investor [Member] Investor [Member] Investor Vor, Karuna & Gelesis Vor, Karuna & Gelesis [Member] Vor, Karuna & Gelesis Performance Share Plan [Abstract] Performance Share Plan [Abstract] Performance Share Plan Forfeited (in shares) Forfeited During the Year Number of options Number of share options forfeited in share-based payment arrangement Disclosure of operating segments [table] Disclosure of operating segments [table] Sale of Assets [Abstract] Sale of Assets [Abstract] Subsequent Events Disclosure of events after reporting period [text block] Capital and Financial Risk Management Disclosure of financial risk management [text block] Long-term loan Disclosure of borrowings [text block] Current liabilities Current liabilities [abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Operating Loss Carryforwards Not Subject To Expiration Operating Loss Carryforwards Not Subject To Expiration [Member] Operating Loss Carryforwards Not Subject To Expiration Disclosure of subsidiaries Disclosure of subsidiaries [text block] Income/(loss) before taxes Income/(loss) before taxes Profit (loss) before tax Disclosure of information about methods, inputs and assumptions used for recognizing revenue over time Disclosure of information about methods, inputs and assumptions used for determining transaction price [text block] Weighted Average number of ordinary shares [Table] Weighted Average number of ordinary shares [Table] Weighted Average number of ordinary shares Class B Common [Member] Class B Common [Member] Class B Common Share-based Payment Expense Category [Axis] Share-based Payment Expense Category [Axis] Share-based Payment Expense Category Disclosure of maturity analysis of operating lease payments [text block] Disclosure of maturity analysis of operating lease payments [text block] Distribution to Tal shareholders Distribution to Tal Shareholders Distribution to Tal Shareholders Revenue recognized on deferred revenue outstanding at prior year end Revenue recognized on deferred revenue outstanding at prior year end Revenue recognized on deferred revenue outstanding at prior year end New Standards and Interpretations Not Yet Adopted [Abstract] New Standards and Interpretations Not Yet Adopted [Abstract] Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity Deferred revenues Adjustments for increase decrease In deferred revenue Adjustments for increase decrease In deferred revenue Outside investors Outside investors [Member] Outside investors resTORbio [Member] resTORbio [Member] resTORbio Accretion on preferred shares Accretion on preferred shares Accretion on preferred shares Weighted average number of ordinary shareholders at December 31, Weighted average number of ordinary shares outstanding Associate common stock held at fair value Associate common stock held at fair value Associate common stock held at fair value Cash derecognized upon loss of control over subsidiary Cash flows from losing control of subsidiaries or other businesses, classified as investing activities Expected dividend yield Expected dividend, share options granted Intra-group eliminations Intra-group eliminations [Member] Intra-group eliminations Impairment of intangible assets Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Intangible Assets Disclosure of intangible assets [text block] Weighted Average [Table] Weighted Average Options granted [Table] Weighted Average [Table] Exercise price of the warrants Exercise price, measurement input [Member] Exercise price, measurement input Finance income/(costs) – IFRS 9 fair value accounting Finance income/(costs) – fair value accounting Finance income/(costs) - fair value accounting Finance income/(costs) - fair value accounting Sale of asset [Line Items] Sale of asset [Line Items] Sale of asset Disclosure of terms and conditions of share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [text block] Mr Stephen Muniz Mr Stephen Muniz [Member] Mr Stephen Muniz Over 10 percent of revenue Over 10 percent of revenue [Member] Over 10 percent of revenue Assets and liabilities [member] Assets and liabilities [member] Disclosure of associates [table] Disclosure of associates [table] Net cash used in operating activities Cash flows from (used in) operating activities Weighted average grant date fair value, RSU outstanding beginning balance (in GBP per share) Weighted average grant date fair value, RSU Ending balance (in GBP per share) Weighted average grant date fair value of other equity instruments outstanding in share-based payment arrangement Weighted average grant date fair value of other equity instruments outstanding in share-based payment arrangement Performance Share Plan [Table] Performance Share Plan [Table] Performance Share Plan [Table] Disclosure Of changes in Financial Liabilities, level 3 fair value - Subsidiary Preferred Shares and Convertible Notes Disclosure Of changes in Financial Liabilities, level 3 fair value - Subsidiary Preferred Shares and Convertible Notes [Text Block] Disclosure Of changes in Financial Liabilities, level 3 fair value - Subsidiary Preferred Shares and Convertible Notes Healthcare benefits Employee benefits expense Change in Accounting Policy Disclosure of voluntary change in accounting policy [text block] Short-term employee benefits Key management personnel compensation, short-term employee benefits Disclosure of Accumulated amortization Disclosure of Accumulated amortization [Text Block] Disclosure of Accumulated amortization Supplemental disclosure of non-cash investment and financing activities: Supplemental disclosure of non-cash investment and financing activities [Abstract] Supplemental disclosure of non-cash investment and financing activities Deferred revenue Deferred income Cash paid for rent (principal + interest) Cash outflow for leases Disclosure of Equity Summary of Equity [Text Block] Summary of Equity Shareholder ownership percentage Weighted average shareholder ownership percentage in associate Weighted average shareholder ownership percentage in associate Revenue - Budgeted Costs to complete [Abstract] Revenue - Budgeted Costs to complete [Abstract] Revenue - Budgeted Costs to complete Operating Loss Carryforwards, Expiration Periods [Domain] Operating Loss Carryforwards, Expiration Periods [Domain] Operating Loss Carryforwards, Expiration Periods Share-based payments Key management personnel compensation, share-based payment Intangible Assets Disclosure of detailed information about intangible assets [line items] Ensof Biosystems, Inc. (held indirectly through Enlight) Ensof Biosystems Inc [Member] Ensof Biosystems Inc Exit valuation multiples Exit valuation multiples [Member] Exit valuation multiples Disclosure of Intangible assets, net Schedule of Intangible assets net [Text Block] Schedule of Intangible assets net Accounting Policies - Leases [Table] Accounting Policies - Leases [Table] Accounting Policies - Leases [Table] Total Credit exposure Adjustments to reconcile net operating loss to net cash used in operating activities: Adjustments to reconcile profit (loss) [abstract] Net increase in cash and cash equivalents Increase (decrease) in cash and cash equivalents Recognition of deferred tax assets not previously recognized Tax Rate Effect of deferred tax assets not previously recognised Tax Rate Effect of deferred tax assets not previously recognised Significant Subsidiary Plans [Table] Significant Subsidiary Plans [Table] Significant Subsidiary Plans [Table] Series B Preferred [Member] Series B Preferred [Member] Series B Preferred Non-controlling interests Non-controlling interests Impairment of investment in associate Impairment of investment in associate Impairment of investment in associate Subsidiaries Description of accounting policy for subsidiaries [text block] Disclosure of Changes in the value of subsidiary preferred shares Changes in the value of subsidiary preferred shares [Text Block] Changes in the value of subsidiary preferred shares Disclosure of financial liabilities [abstract] Aggregated time bands [member] Aggregated time bands [member] Disclosure of number and weighted average remaining contractual life of outstanding share options [table] Disclosure of number and weighted average remaining contractual life of outstanding share options [table] Sale of asset Sale of asset Sale of asset Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items] Dr Bharatt Chowrira Dr Bharatt Chowrira [Member] Dr Bharatt Chowrira Expected term Expected term, measurement input [Member] Expected term, measurement input Company and certain preferred shareholders Company and certain preferred shareholders [Member] Company and certain preferred shareholders Weighted Average Options granted [Line Items] Weighted Average Options granted [Line Items] Weighted Average Options granted Disclosure of operating segments Disclosure of operating segments [text block] Weighted Average Options granted [Abstract] Weighted Average Options granted [Abstract] Weighted Average Options granted 1.00 to 2.00 Exercise Price Range Two [Member] Exercise Price Range Two [Member] Borrowings, Reclassification of accrued interest to other current liabilities Borrowings, Reclassification of accrued interest to other current liabilities Borrowings, Reclassification of accrued interest to other current liabilities Interest received Interest received, classified as operating activities Adjustment for initial application of IFRS 16 Adjustment for initial application of IFRS 16 adjustment Adjustment for the initial application of IFRS 16 Cumulative Effect, Period of Adoption, Adjustment [Member] Related party transactions [Table] Related party transactions [Table] Related party transactions Disclosure of other operating expense Disclosure of other operating expense [text block] Certain preferred shareholders Certain preferred shareholders [Member] Certain preferred shareholders Accounts receivable Receivables from contracts with customers Entity Registrant Name Entity Registrant Name Financial Instruments - Warrants [Table] Financial Instruments - Warrants [Table] Financial Instruments - Warrants [Table] R&D and orphan drug tax credits Rate of Research And Development and orphan drug tax credits Rate of Research And Development and orphan drug tax credits Equity price risk [member] Equity price risk [member] Share-based Payment Expense [Abstract] Share-based Payments [Abstract] Share-based Payments [Abstract] Foreign [Member] Foreign [Member] Foreign Financial Instruments, Significant Unobservable inputs, level 3 fair value - Preferred Shares liability Financial Instruments, Significant Unobservable inputs, level 3 fair value - Preferred Shares liability [Text Block] Financial Instruments, Significant Unobservable inputs, level 3 fair value - Preferred Shares liability Weighted average [member] Weighted average [member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating segments [member] Operating segments [member] Appeering Inc. Appeering Appeering [Member] Appeering Gain/(loss) on disposal of assets Gains (losses) on disposals of non-current assets Income of partnerships not subject to tax Tax effect of revenues exempt from taxation Nontrading Holding Companies [Member] Nontrading Holding Companies [Member] Nontrading Holding Companies Impairment of investment Impairment loss (reversal of impairment loss) recognised in profit or loss Entity Address, Postal Zip Code Entity Address, Postal Zip Code Market – Backsolve & Hybrid allocation Market approach [member] PureTech LYT (formerly Ariya Therapeutics, Inc.) PureTech LYT [Member] PureTech LYT [Member] PureTech LYT American Depositary Shares American Depositary Shares [Member] American Depositary Shares Total current liabilities Current liabilities Current liabilities Deferred Tax Assets and Liabilities [Line Items] Deferred Tax Assets and Liabilities [Line Items] Deferred Tax Assets and Liabilities Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities, warrants Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities, warrants [Text Block] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities, warrants Inactive Subsidiaries [Member] Inactive Subsidiaries [Member] Inactive Subsidiaries Subsidiary dividend payments Subsidiary dividend payments Subsidiary dividend payments Trade and other payables Total trade and other payables Trade and other current payables Percent voting rights of the Companny Percent voting rights of the Companny Percent voting rights of the Companny Earnings Loss per Share [Line Items] Earnings Loss per Share [Line Items] Earnings Loss per Share Total Type of Lease Total Type of Lease [Member] Total Type of Lease Enlight Biosciences, LLC Enlight [Member] Enlight [Member] Enlight Related party transactions [abstract] Related party transactions [abstract] Convertible Notes [Line Items] Convertible Notes [Line Items] Convertible Notes Disclosure of Weighted Average Exercise Prices for Options Outstanding Disclosure of Weighted Average Exercise Prices for Options Outstanding [Text Block] Disclosure of Weighted Average Exercise Prices for Options Outstanding Basic [Member] Basic [Member] Basic Property and Equipment Description of accounting policy for property, plant and equipment [text block] Financial liabilities, class [member] Financial liabilities, class [member] Level 1 of fair value hierarchy [member] Level 1 of fair value hierarchy [member] Increase and Decrease Through Change In NCI Share In Subsidiary Deficit Increase and Decrease Through Change In NCI Share In Subsidiary Deficit Increase and Decrease Through Change In NCI Share In Subsidiary Deficit Current year losses for which no deferred tax asset is recognized Tax effect of tax losses Operating income/(loss) Profit (loss) from operating activities Weighted-average exercise price, beginning of year (in GBP per share) Weighted-average exercise price, end of year (in GBP per share) Weighted average exercise price Weighted average exercise price of share options outstanding in share-based payment arrangement Disclosure of maturity analysis of finance lease payments receivable [table] Disclosure of maturity analysis of finance lease payments receivable [table] Subsidiary Notes Payable - Loans [Line Items] Subsidiary Notes Payable - Loans [Line Items] Subsidiary Notes Payable - Loans Significant Subsidiary Plan Karuna 2009 Plan - Range of assumptions of Fair Value of stock option grants Significant Subsidiary Plan Karuna 2009 Plan - Range of assumptions of Fair Value of stock option grants [Text Block] Significant Subsidiary Plan Karuna 2009 Plan - Range of assumptions of Fair Value of stock option grants Retained earnings/(accumulated deficit) Retained earnings Liabilities [member] Liabilities [member] Acquisition of equity instruments in other entities Acquisition of equity instruments in other entities Acquisition of equity instruments in other entities Sensitivity analysis for equity price risk, impact on pre-tax earnings Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings Customers over 10% of revenue* Major customers [axis] Deconsolidated former Subsidiary Operating Companies [Member] Deconsolidated former Subsidiary Operating Companies [Member] Deconsolidated former Subsidiary Operating Companies Weighted Average Options forfeited [Table] Weighted Average Options forfeited [Table] Weighted Average Options forfeited [Table] Revenue [Line Items] Revenue [Line Items] Revenue Libra Biosciences, Inc. Libra Biosciences Inc [Member] Libra Biosciences Inc Non-audit related services Auditor's remuneration for other services Impairment of investment in associate Adjustment of Impairment of investment in associate Adjustment of Impairment of investment in associate Investments held at fair value Beginning balance Ending balance Non-current financial assets at fair value through profit or loss Purchase option agreement, gross proceeds threshold Purchase option agreement, gross proceeds threshold Purchase option agreement, gross proceeds threshold Deconsolidation Increase in investments due to retained non-controlling interest in former subsidiaries Increase in investments due to retained non-controlling interest in former subsidiaries Gain on deconsolidation Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates At fair value [member] At fair value [member] Financial assets Financial assets Operating Expenses Table [Table] Operating Expenses Table [Table] Operating Expenses Table PureTech Securities Corp. PureTech Securities Corp. [Member] PureTech Securities Corp. Proportion of ownership interests held by non-controlling interests Proportion of ownership interests held by non-controlling interests Initial Public Offering [Member] Initial Public Offering [Member] Initial Public Offering Series C Preferred [Member] Series C Preferred [Member] Series C Preferred Cost Approach & OPM allocation Cost approach [member] Interest Expense from other borrowings Interest Expense from other borrowings Interest Expense from other borrowings Fair value input, common stock price Fair Value Input, Common Stock Price Fair Value Input, Common Stock Price Exercised (in shares) Exercised During the Year Number of share options exercised in share-based payment arrangement Foreign currency translation differences Foreign exchange gain (loss) Disclosure of Long-term loan - Vedanta Disclosure of borrowing costs [text block] Profit or loss [abstract] Document Fiscal Year Focus Document Fiscal Year Focus Disclosure of Income Taxes Recognized in Comprehensive Income Disclosure of Income Taxes Recognized in Comprehensive Income [Text Block] Disclosure of Income Taxes Recognized in Comprehensive Income Sensitivity analysis for equity price risk, impact on pre-tax earnings, percentage Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percentage Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percentage Dr John LaMattina and Ms Mary LaMattina Dr John LaMattina and Ms Mary LaMattina [Member] Dr John LaMattina and Ms Mary LaMattina Leasehold improvements purchased through lease incentives (deducted from Right of Use Asset) Leasehold improvements purchased through lease incentives Leasehold improvements purchased through lease incentives Share-based Payments Table [Table] Share-based Payments Table [Table] Share-based Payments Table [Table] Financial Instruments Description of accounting policy for financial instruments [text block] Entity Current Reporting Status Entity Current Reporting Status Purchase of non controlling interest in consideration for issuance of shares and options Purchase of non controlling interest in consideration for issuance of shares and options Purchase of non controlling interest in consideration for issuance of shares and options Total other comprehensive income/(loss) Other comprehensive income Other comprehensive income Trade payables Current trade payables All levels of fair value hierarchy [member] All levels of fair value hierarchy [member] Other research and development expenses Other Research And Development Expense Other Research And Development Expense Sale of investments held at fair value Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities Share-based payment measurement Rate of Share based Payment Measurement Rate of Share based Payment Measurement Conversion to preferred Conversion to preferred Conversion to preferred Deferred tax assets and liabilities [abstract] Borrowings by name [axis] Borrowings by name [axis] Useful life measured as period of time, property, plant and equipment Useful life measured as period of time, property, plant and equipment Classes of share capital [axis] Classes of share capital [axis] Deferred tax assets (liabilities), net, not recognized Net deferred tax assets, not recognised Net deferred tax assets, not recognised Transaction Costs Transaction Costs Transaction Costs Payroll Taxes Payroll Taxes Payroll Taxes Consolidated Statements of Financial Position Statement of financial position [abstract] Subsidiary Notes Payable [Abstract] Subsidiary Notes Payable [Abstract] Subsidiary Notes Payable [Abstract] Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Schedule of Notes Payable Schedule of Notes Payable [Text Block] Schedule of Notes Payable Maturity [axis] Maturity [axis] Share-based payments Share-based payments Share-based payments Weighted average remaining contractual life of options excisable Weighted average remaining contractual life of options excisable Weighted average remaining contractual life of options excisable Liquidity Risk [Line Items] Liquidity Risk [Line Items] Liquidity Risk Entity Address, City or Town Entity Address, City or Town Notes payable Notes and debentures issued Neither past due or impaired Financial assets neither past due nor impaired [member] Sublease Sublease [Member] Sublease Gain/(loss) on foreign currency exchange Gain Loss on foreign currency exchange in finance costs Gain Loss on foreign currency exchange in finance costs Vor Biopharma Inc. Vor [Member] Vor [Member] Vor Sale of asset, deposited into escrow Sale of asset, deposited into escrow Sale of asset, deposited into escrow Balance before allocation of share in associate loss to long-term interest Financial Assets At Fair Value Through Profit Or Loss before allocation to long-term interest Financial Assets At Fair Value Through Profit Or Loss before allocation to long-term interest Preference shares [member] Preference shares [member] Types of customers [member] Types of customers [member] Current year losses for which no deferred tax asset is recognized Tax rate effect of tax losses Interest paid Interest paid, classified as operating activities Classes of liabilities [axis] Classes of liabilities [axis] Non-Controlling Interests [Table] Non-Controlling Interests [Table] Non-Controlling Interests Business Contact Business Contact [Member] Long-term loan [Abstract] Long-term loan [Abstract] Entity's total for subsidiaries [member] Entity's total for subsidiaries [member] Other income/(expense) Other income Outstanding, beginning of year (in shares) Outstanding, end of year (in shares) Number of other equity instruments outstanding in share-based payment arrangement Entity's total for associates [member] Entity's total for associates [member] Components of equity [axis] Components of equity [axis] Conversion of note receivable Conversion of note receivable Conversion of note receivable Impairment of financial assets [axis] Impairment of financial assets [axis] Weighted average number of ordinary shareholders at December 31, Adjusted weighted average number of ordinary shares outstanding Subsidiary dividends Dividends recognised as distributions to non-controlling interests Investment, Name [Domain] Investment, Name [Domain] Minimum liquidation preference [Abstract] Minimum liquidation preference [Abstract] Minimum liquidation preference Translation reserve [member] Reserve of exchange differences on translation [member] Deferred tax liabilities, net, recognized Net deferred tax liabilities Recognised Income Tax Expense [Table] Recognised Income Tax Expense [Table] Recognised Income Tax Expense [Table] Reconciliation of Effective Tax Rate [Table] Reconciliation of Effective Tax Rate [Table] Reconciliation of Effective Tax Rate [Table] Depreciation and amortization Adjustments for depreciation and amortisation expense Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [abstract] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [abstract] Sensitivity Range Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Period Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Period Proportion of ownership interest in subsidiary, additional ownership acquired Proportion of ownership interest in subsidiary, additional ownership acquired Proportion of ownership interest in subsidiary, additional ownership acquired Investments in Associates Disclosure of associates [text block] Convertible Notes [Member] Convertible Notes [Member] Convertible Notes Credit Risk Abstract [Abstract] Liquidity Risk [Abstract] Liquidity Risk Other temporary differences Other Deferred tax assets Other Deferred tax assets Weighted Average Options outstanding [Table] Weighted Average Options outstanding [Table] Weighted Average Options outstanding [Table] Financial Instruments - Warrants [Roll Forward] Financial Instruments - Warrants [Roll Forward] Financial Instruments - Warrants Document Fiscal Period Focus Document Fiscal Period Focus Purchase of interests in associates Cash purchase of preferred shares Purchase of interests in associates Series 3 Growth Preferred Stock Series 3 Growth Preferred Stock [Member] Series 3 Growth Preferred Stock Investments held at fair value [Table] Investments held at fair value [Table] Investments held at fair value Financial Instruments - Warrants [Line Items] Financial Instruments - Warrants [Line Items] Financial Instruments - Warrants Development Costs Description of accounting policy for research and development expense [text block] Non-controlling interests [member] Non-controlling interests [member] Cash flows from operating activities Cash flows from (used in) operating activities [abstract] Subsidiary Plans [Table] Subsidiary Plans [Table] Subsidiary Plans [Table] Summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations [Table] Summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations [Table] Summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations Exercise of share-based awards Increase (decrease) through exercise of options, equity Gain on deconsolidation [Abstract] Gain on deconsolidation [Abstract] Gain on deconsolidation Finance Income and Finance Costs Description of accounting policy for finance income and costs [text block] Entity Filer Category Entity Filer Category Weighted Average Options forfeited [Abstract] Weighted Average Options forfeited [Abstract] Weighted Average Options forfeited (Loss)/income before taxes pre IAS 39 fair value accounting, finance costs – subsidiary preferred shares, share-based payment expense, depreciation of tangible assets and amortization of intangible assets Profit Loss Before Tax pre IAS 39 Profit Loss Before Tax pre IAS 39 Income/(loss) attributable to ordinary shareholders Profit Loss Attributable To Ordinary Shareholders Profit Loss Attributable To Ordinary Shareholders Operating Expenses Disclosure Of Operating Expense Explanatory [Text Block] Disclosure Of Operating Expense Explanatory 2.00 to 3.00 Exercise Price Range Three [Member] Exercise Price Range Three [Member] Accounting Policies Accounting Policies [Line Items] Accounting Policies Leases [Abstract] Leases [Abstract] Forfeited (in shares) Number of other equity instruments forfeited in share-based payment arrangement Finance lease payments receivable [Line Items] Finance lease payments receivable [Line Items] Finance lease payments receivable Disclosure of detailed information about borrowings [line items] Disclosure of detailed information about borrowings [line items] Dame Marjorie Scardino Dame Marjorie Scardino [Member] Dame Marjorie Scardino Disclosure of short-term and long-term portion of lease liability Disclosure of short-term and long-term portion of lease liability [Text Block] Disclosure of short-term and long-term portion of lease liability Non-Controlling Interests [Line Items] Non-Controlling Interests [Line Items] Non-Controlling Interests Schedule of Contract Balances Schedule of Contract Balances [Text Block] Schedule of Contract Balances Financial Asset Increase/ (Decrease) Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets Minimum liquidation preference [Table] Minimum liquidation preference [Table] Minimum liquidation preference [Table] Gain/(Loss) from change in fair value of warrant liability Gain/(Loss) from change in fair value of warrant liability Gain/(Loss) from change in fair value of warrant liability Par value per share Par value per share Adjustments Adjustments, right-of-use assets Adjustments, right-of-use assets Revision of Prior Period [Domain] Revision of Prior Period [Domain] PureTech Management, Inc. PureTech Management [Member] PureTech Management Disclosure of detailed information about borrowings [table] Disclosure of detailed information about borrowings [table] 2017 Performance Based RSU [Member] 2017 Performance Based RSU [Member] 2017 Performance Based RSU Lease liability, non-current Long-term Portion of Lease Liability Non-current lease liabilities Types of risks [axis] Types of risks [axis] Audit of the financial statements of subsidiaries Audit of financial statements of subsidiaries Audit of financial statements of subsidiaries Mr Christopher Viehbacher Mr Christopher Viehbacher [Member] Mr Christopher Viehbacher Total other operating expenses Miscellaneous other operating expense Unrealized (gain)/loss on foreign currency transactions Adjustments for unrealised foreign exchange losses (gains) Earnings/(Loss) attributable to owners of the Company [Abstract] Earnings/(Loss) attributable to owners of the Company [Abstract] Earnings/(Loss) attributable to owners of the Company Related Parties Transactions Disclosure of transactions between related parties [text block] Weighted average grant date fair value, RSU forfeited (in GBP per share) Weighted average grant date fair value of other equity instruments forfeited in share-based payment arrangement Weighted average grant date fair value of other equity instruments forfeited in share-based payment arrangement Mandara Sciences, LLC Mandara Sciences LLC [Member] Mandara Sciences LLC Expected terms (in years) Option life, share options granted Revenue [abstract] Revenue [abstract] Maximum authorized amount, percentage of ordinary shares outstanding Share-based Payment Arrangements, Authorized Amount, Percentage of Common Shares Outstanding Share-based Payment Arrangements, Authorized Amount, Percentage of Common Shares Outstanding Expired During the Year Number of share options expired in share-based payment arrangement Geographical areas [member] Geographical areas [member] Gain on forgiveness of debt Gain on forgiveness of debt Gain on forgiveness of debt Operating Expense Category [Axis] Operating Expense Category [Axis] Operating Expense Category Increase in value of preferred shares measured at fair value Change in fair value Change in fair value Change in fair value Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets Loss on impairment of intangible asset Impairment loss recognised in profit or loss, intangible assets other than goodwill Types of customers [axis] Types of customers [axis] Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Disclosure of recognized income tax expense Disclosure of recognized income tax expense [Text Block] Disclosure of recognized income tax expense Revenue Budget estimate to satisfy revenue performance obligation Budget estimate to satisfy revenue performance obligation Financial Instruments - Fair value Measurement and Classification [Line Items] Financial Instruments - Fair value Measurement and Classification [Line Items] Financial Instruments - Fair value Measurement and Classification Equity [member] Equity [member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Gain on deconsolidation Deconsolidation, Gain (Loss), Amount Deconsolidation, Gain (Loss), Amount Short-term and Long-term portion of lease liability [Table] Short-term and Long-term portion of lease liability [Table] Short-term and Long-term portion of lease liability Entity Emerging Growth Company Entity Emerging Growth Company Weighted-average statutory rate Tax expense (income) at applicable tax rate Convertible Notes [Table] Convertible Notes [Table] Convertible Notes [Table] Proportion of ownership interest in associate Proportion of ownership interest in associate Volatility Expected volatility Historical volatility for shares, measurement input [member] Payment of lease liability Payments of lease liabilities, classified as financing activities Disclosure of detailed information about intangible assets [abstract] Finance costs [Abstract] Finance costs [Abstract] Finance costs Statement of changes in equity [line items] Statement of changes in equity [line items] Equity settled share-based payment expense Adjustments for share-based payments Leases - Rental [Table] Leases - Rental [Table] Leases - Rental [Table] Prepaid expenses and other current assets Adjustments for decrease (increase) in other current assets Other Financial Assets Disclosure of other assets [text block] Maximum Maximum [Member] Measurement Input, Probability Of Occurrence Measurement Input, Probability Of Occurrence [Member] Measurement Input, Probability Of Occurrence Other liabilities Adjustments for increase (decrease) in other operating payables Contact Personnel Name Contact Personnel Name Major ordinary share transactions [member] Major ordinary share transactions [member] Net cash provided by financing activities Cash flows from (used in) financing activities Disclosure of Long-term loan obligations Disclosure of long-term loan obligations [Text Block] Disclosure of long-term loan obligations Non-controlling interests Comprehensive income, attributable to non-controlling interests Undiscounted operating lease payments to be received Undiscounted operating lease payments to be received Goodwill Goodwill Trading Symbol Trading Symbol Information about credit quality of neither past due nor impaired financial assets Information about credit quality of neither past due nor impaired financial assets [text block] Disclosure of changes in assets, level 3 fair value - investments held at fair value [Text Block] Disclosure of changes in assets, level 3 fair value - investments held at fair value [Text Block] Disclosure of changes in assets, level 3 fair value - investments held at fair value Investments held at fair value [Line Items] Investments held at fair value [Line Items] Investments held at fair value Rental expense Rental expense Investments held at fair value Investments held at fair value [Member] Investments held at fair value Earnings Loss per Share [Table] Earnings Loss per Share [Table] Earnings Loss per Share [Table] Debt instrument, payment terms, final fee trigger amount Debt instrument, payment terms, final fee trigger amount Debt instrument, payment terms, final fee trigger amount Trade and other payables Adjustments for increase (decrease) in trade accounts payable Trade and other receivables Trade and other current receivables Disclosure of range of exercise prices of outstanding share options [line items] Disclosure of range of exercise prices of outstanding share options [line items] Share of net (income)/loss of associates accounted for using the equity method Adjustments for share of net income(loss) of associate Adjustments for share of net income(loss) of associate Customers over 10% of revenue* Customers [member] Entity Shell Company Entity Shell Company Subsidiary Preferred Shares [Line Items] Subsidiary Preferred Shares [Line Items] Subsidiary Preferred Shares Gain on deconsolidation [Line Items] Gain on deconsolidation [Line Items] Gain on deconsolidation Contract duration [axis] Contract duration [axis] Document Accounting Standard Document Accounting Standard Document Type Document Type Purchase of subsidiary’s non-controlling interest through issuance of shares Increase Decrease through purchase of subsidiary non-controlling interest through issuance of shares, equity Increase Decrease through purchase of subsidiary non-controlling interest through issuance of shares, equity Net finance income/(costs) Finance income/(costs), net Finance Costs Finance income (cost) Granted (in shares) Granted During the Year Number of share options granted in share-based payment arrangement Additions, net of transfers Additions other than through business combinations, property, plant and equipment Net assets attributable to shareholders Net assets attributable to shareholders of associate Net assets attributable to shareholders of associate Directors and Senior Managers Shareholdings and Share Incentive awards [Table] Directors and Senior Managers Shareholdings and Share Incentive awards [Table] Directors and Senior Managers Shareholdings and Share Incentive awards PureTech Securities II Corp. PureTech Securities II Corp. [Member] PureTech Securities II Corp. Dr Joep Muijrers Dr Joep Muijrers [Member] Dr Joep Muijrers Realized loss on sale of investments Adjustments for losses (gains) on disposal of non-current assets Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] Disclosure of RSU activity Disclosure of number and weighted average exercise prices of other equity instruments [text block] Classes of financial assets [axis] Classes of financial assets [axis] Financial Instruments Liabilities, Warrants, Sensitivity [Table] Financial Instruments Liabilities, Warrants, Sensitivity [Table] Financial Instruments Liabilities, Warrants, Sensitivity [Table] Type of Lease [Axis] Type of Lease [Axis] Type of Lease Long-term loan Non-current financial liabilities Sensitivity Range Percentage of reasonably possible decrease in unobservable input, assets Share price of investee shares Share purchase price Share price of investee shares Share price of investee shares Discount rate Discount rate, measurement input [member] Ranges [member] Ranges [member] Deconsolidation of subsidiaries Decrease through loss of control of subsidiary, property, plant and equipment Summary of changes in equity classified non-controlling ownership interests in subsidiaries Disclosure of interests in subsidiaries [text block] Cash investment in Associate Cash investment in Associate Cash investment in Associate Weighted average assumptions [Abstract] Share-based payment - Weighted average assumptions Total Business Or Sourcing Company [Member] Total Business Or Sourcing Company [Member] Total Business Or Sourcing Company Average effective tax rate Average effective tax rate Series A-1 Preferred [Member] Series A-1 Preferred [Member] Series A-1 Preferred Property and Equipment Disclosure of property, plant and equipment [text block] Number Of Shares Held Number Of Shares Held Number Of Shares Held Bottom of range [member] Bottom of range [member] Conversion to common Conversion to common Conversion to common Disclosure of associates [Line Items] Disclosure of associates [Line Items] Disclosure of associates Leases Disclosure of leases [text block] Valuation techniques used in fair value measurement [axis] Valuation techniques used in fair value measurement [axis] Accretion on preferred shares Rate of accretion on preferred shares Rate of accretion on preferred shares Total deferred income tax expense/(benefit) Deferred tax expense (income) Balance Share Capital (in shares) Balance Share Capital (in shares) Number of shares issued Number of shares issued Dr John LaMattina (individually) Dr John LaMattina (individually) [Member] Dr John LaMattina (individually) Types of interest rates [axis] Types of interest rates [axis] Entity Address, State or Province Entity Address, State or Province Cost Principal Gross carrying amount [member] Share premium [member] Share premium [member] Related Party Transactions - Key Management Personnel Compensation [Abstract] Related Party Transactions - Key Management Personnel Compensation Operating Expenses [Table] Operating Expenses [Table] Operating Expenses [Table] Neither Past due or impaired [Table] Neither Past due or impaired [Table] Neither Past due or impaired [Table] Commitments And Contingencies [Abstract] Commitments And Contingencies [Abstract] Gross Principal Gross Principal Gross Principal Borrowings, adjustment to interest rate basis Borrowings, adjustment to interest rate basis Disclosure of Lease Liabilities Disclosure of Lease Liabilities [Text Block] Disclosure of Lease Liabilities Total Finance Income Cost Total Finance Income Cost Total Finance Income Cost Disclosure of estimated useful life of assets Disclosure of estimated useful life of assets [Text Block] Disclosure of estimated useful life of assets Weighted average exercise price, options granted (in GBP per share) Weighted average exercise price Weighted average exercise price of share options granted in share-based payment arrangement Karuna Pharmaceuticals, Inc. Karuna [Member] Karuna [Member] Karuna Level 3 of fair value hierarchy [member] Level 3 of fair value hierarchy [member] Taxation Income tax expense/(benefit) Income tax expense/(benefit) Tax expense (income) Earnings Category Axis [Axis] Earnings Category [Axis] Earnings Category Other current liabilities Other current liabilities Exchange differences Increase (decrease) through net exchange differences, property, plant and equipment Other Other tax effects for reconciliation between accounting profit and tax expense (income) 2023 Two to three years Later than two years and not later than three years [member] Finance income/(costs) – fair value accounting Total Finance income/(costs) - fair value accounting Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities Disclosure of Subsidiary Share-based Payments Disclosure of Subsidiary Share-based Payment Plans [Text Block] Disclosure of Subsidiary Share-based Payment Plans Deferred tax assets, net, recognized Net deferred tax assets Aggregate principal amount Notional amount Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Budgeted costs to complete Rate of Budget estimate to satisfy revenue performance obligation Rate of Budget estimate to satisfy revenue performance obligation Income taxes, net Adjustments for income tax expense Vesting of restricted stock units (RSU) Increase Decrease through vesting of RSU, equity Increase Decrease through vesting of RSU, equity Reclassification of investment to investment in associate Reclassification of investment to investment in associate Reclassification of investment to investment in associate Weighted average exercise price, options forfeited (in GBP per share) Weighted average exercise price Weighted average exercise price of share options forfeited in share-based payment arrangement Subsidiary Enterprise Value Investee Enterprise Value Enterprise Value, measurement input 1 [Member] Enterprise Value, measurement input 1 Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Share-based payment arrangement, cash settlement value Share-based Payment Arrangement, Cash Used to Settle Award Share-based Payment Arrangement, Cash Used to Settle Award Aggregated measurement [member] Aggregated measurement [member] Gain on loss of significant influence Gain/(Loss) on loss of significant influence Gain/(Loss) on loss of significant influence Karuna Therapeutics, Inc. Karuna Therapeutics, Inc. [Member] Karuna Therapeutics, Inc. State [Member] State [Member] State Deferred revenue Deferred revenue – long term Non-current contract liabilities Other not including Gelesis, Vedanta and Karuna [Member] Other not including Gelesis, Vedanta and Karuna [Member] Other not including Gelesis, Vedanta and Karuna Document Shell Company Report Document Shell Company Report Commitments and Contingencies Disclosure of commitments and contingent liabilities [text block] Audit of these financial statements Auditor's remuneration for audit services Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Unearned Finance income Unearned finance income relating to finance lease payments receivable Deconsolidated Deconsolidated Lease Liabilities Deconsolidated Lease Liabilities 2022 One to two years Later than one year and not later than two years [member] Borrowings by name [member] Borrowings by name [member] Entity Voluntary Filers Entity Voluntary Filers (Gain)/loss on short-term investments Adjustments for decrease (increase) in financial assets held for trading Number of associate's common stock held at fair value Number of associate common stock held at fair value Number of associate common stock held at fair value Research And Development [Member] Research And Development [Member] Research And Development Effects of state tax rate in US Effects of state tax rate in US Effects of state tax rate in US Sale of shares Sales, fair value measurement, assets Series A-3 Preferred [Member] Series A-3 Preferred [Member] Series A-3 Preferred Three to Twelve months Later than three months and not later than one year [member] Disclosure of financial assets [line items] Disclosure of financial assets [line items] Non-current assets Non-current assets [abstract] Significant Subsidiary Plans [Abstract] Significant Subsidiary Plans [Abstract] Significant Subsidiary Plans Other non-current assets Other non-current assets Finance income/(costs): Finance income/(costs) [Abstract] Finance income/(costs) 2024 Three to four years Later than three years and not later than four years [member] Sale of equity instruments in other entities Sale of equity instruments in other entities Sale of equity instruments in other entities Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies Vedanta Biosciences, Inc. Vedanta [Member] Vedanta Biosciences [Member] Vedanta Biosciences Assets [member] Assets [member] Net cash provided by/(used in) investing activities Cash flows from (used in) investing activities Total revenue Revenue Revenue Property, plant and equipment [Table] Disclosure of detailed information about property, plant and equipment [table] Disclosure of Other Financial Assets Other Financial Assets [Text Block] Other Financial Assets Performance based RSU [Member] Performance based RSU [Member] Performance based RSU Financial Liability Increase/ (Decrease) Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities Top of range [member] Top of range [member] Laboratory and manufacturing equipment Laboratory and Manufacturing Equipment [Member] Laboratory and Manufacturing Equipment Money Markets [member] Loans to corporate entities [member] Disclosure of financial liabilities - Warrants, weighted-average assumptions Disclosure of financial liabilities - Warrants, weighted-average assumptions [Text Block] Disclosure of financial liabilities - Warrants, weighted-average assumptions Issuance of placing shares (in shares) Increase (decrease) in number of shares outstanding Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract] Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract] Deconsolidated Deconsolidation Right-of-use Assets Deconsolidation Right-of-use Assets Ranges of exercise prices for outstanding share options [axis] Ranges of exercise prices for outstanding share options [axis] Capital And Financial Risk Management [Abstract] Capital And Financial Risk Management Weighted average exercise price, options exercised (in GBP per share) Weighted average exercise price of share options exercised in share-based payment arrangement Purchase of subsidiary non-controlling interest through issuance of shares (in shares) Increase Decrease through purchase of subsidiary non-controlling interest through issuance of shares Increase Decrease through purchase of subsidiary non-controlling interest through issuance of shares Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [abstract] Akili Interactive Labs, Inc. Akili Interactive Labs [Member] Akili Interactive Labs Entity Central Index Key Entity Central Index Key Exercise of stock options Proceeds from exercise of options Taxation Description of accounting policy for income tax [text block] Segment consolidation items [axis] Segment consolidation items [axis] Revenue Disclosure of revenue [text block] Total Income Tax Type [Member] Total Income Tax Type [Member] Total Income Tax Type Neither past due nor impaired [Line Items] Neither past due nor impaired [Line Items] Neither past due nor impaired PureTech LYT-100 PureTech LYT - 100 [Member] PureTech LYT - 100 Financial Liability Increase/ (Decrease) Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities Disclosure of Subsidiary preferred shares, Minimum liquidation preference Summary of Minimum liquidation preference [Text Block] Summary of Minimum liquidation preference Proceeds from issuance of convertible notes Proceeds from issuance of convertible notes Proceeds from issuance of convertible notes Rental income Rental income Current assets Current assets [abstract] Share-based Payment [Line Items] Share-based Payment [Line Items] Share-based Payment Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Total equity and liabilities Equity and liabilities Finance income/(costs) – subsidiary preferred shares Total Finance income/(costs) - subsidiary preferred shares Finance income/(costs) - subsidiary preferred shares Finance income/(costs) - subsidiary preferred shares Series C-2 Preferred [Member] Series C-2 Preferred [Member] Series C-2 Preferred Deferred revenue Deferred revenue – short term Current contract liabilities Diluted [Member] Diluted [Member] Diluted Weighted Average Options exercisable [Abstract] Weighted Average Options exercisable [Abstract] Weighted Average Options exercisable Disclosure of information about employees Disclosure of information about employees [text block] Provisions Description of accounting policy for provisions [text block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disclosure of information of employees [Table] Disclosure of information of employees [Table] Disclosure of information of employees [Table] Statement of changes in equity [table] Statement of changes in equity [table] Accrued interest Borrowings, Accrued Interest Borrowings, Accrued Interest Discount for lack of marketability ("DLOM") Discount for lack of marketability, measurement input [Member] Discount for lack of marketability, measurement input Disclosure of Earnings/(Loss) per Share Schedule of Earnings per Share [Text Block] Schedule of Earnings per Share Gain/(Loss) from change in fair value of preferred shares and convertible debt Gain/(Loss) from change in fair value of preferred shares and convertible debt Gain/(Loss) from change in fair value of preferred shares and convertible debt Non-controlling interests Profit (loss), attributable to non-controlling interests Risk-free interest rate Risk free interest rate, share options granted Level 2 of fair value hierarchy [member] Level 2 of fair value hierarchy [member] Share price at grant date Weighted average share price, share options granted Reconciliation of average effective tax rate and applicable tax rate [abstract] Translation reserve Reserve of exchange differences on translation Preferred Shares and Warrant Preferred Shares and Warrant [Member] Preferred Shares and Warrant Employee Benefits Description of accounting policy for employee benefits [text block] Convertible Notes [Roll Forward] Convertible Notes [Roll Forward] Convertible Notes Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents Description of accounting policy for restricted cash and cash equivalents [text block] Mark to Market investment in subsidiary Mark to Market investment in subsidiary Mark to Market investment in subsidiary Lease liability, current Short-term Portion of Lease Liability Lease Liability Current lease liabilities Gain on loss of significant influence Adjustments for gain on loss of significant influence Adjustments for gain on loss of significant influence Total income tax expense/(benefit), recognized Deferred tax expense (income) recognised in profit or loss IFRS 15, Revenue from Contracts with Customers Description of accounting policy for recognition of revenue [text block] Associates [axis] Associates [axis] Purchase of minority interest Purchase of minority interest Purchase of minority interest Remaining Performance Obligation Performance obligations satisfied over time [member] Property, plant and equipment Disclosure of detailed information about property, plant and equipment [line items] Consolidated Statements of Comprehensive Income/(Loss) Statement of comprehensive income [abstract] Accumulated amortization Accumulated depreciation and amortisation [member] Deferred tax assets (liabilities), net Deferred tax liability (asset) Unused tax losses for which no deferred tax asset recognised Unused tax losses for which no deferred tax asset recognised Disclosure of significant unobservable inputs used in fair value measurement of assets [table] Disclosure of significant unobservable inputs used in fair value measurement of assets [table] Shares remaining available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Shares Remaining Available For Issuance Share-based Compensation Arrangement by Share-based Payment Award, Shares Remaining Available For Issuance Equity settled share-based payments Increase (decrease) through share-based payment transactions, equity Common shares [member] Ordinary shares [member] Budgeted Costs to complete [Line Items] Budgeted Costs to complete [Line Items] Budgeted Costs to complete Balance at beginning of period Balance at end of period Financial assets, at fair value Financial assets Financial assets, at fair value Disclosure of range of exercise prices of outstanding share options [table] Disclosure of range of exercise prices of outstanding share options [table] Liabilities Liabilities [abstract] Impairment Description of accounting policy for impairment of non-financial assets [text block] Disclosure of maturity analysis of operating lease payments [line items] Disclosure of maturity analysis of operating lease payments [line items] Significant Subsidiary Plan [Line Items] Significant Subsidiary Plan [Line Items] Significant Subsidiary Plan Investment in subsidiaries Investments in subsidiaries Earnings/(Loss) per Share Disclosure of earnings per share [text block] Financial Asset Increase/ (Decrease) Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss, net of tax Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss, net of tax Classes of assets [axis] Classes of assets [axis] Disclosure of finance income (cost) [text block] Disclosure of finance income (cost) [text block] PureTech Health LLC PureTech Health LLC PureTech Health [Member] PureTech Health General and administrative expenses General and administrative expenses General and administrative expense Directors [Abstract] Directors [Abstract] Directors Tal Merger Agreement [Abstract] Tal Merger Agreement [Abstract] Liquidity Risk [Table] Liquidity Risk [Table] Liquidity Risk [Table] Capital And Financial Risk Management [Table] Capital And Financial Risk Management [Table] Capital And Financial Risk Management Total liabilities Total liabilities Liabilities Disposal of assets Adjustments for gain (loss) on disposals, property, plant and equipment Total non-current assets Non-current assets Non-current assets Additions Additions to right-of-use assets Issued capital [member] Issued capital [member] Contractual Interest expense on convertible notes Contractual Interest expense on convertible notes Contractual Interest expense on convertible notes Assets and liabilities [axis] Assets and liabilities [axis] Weighted Average Options Outstanding [Line Items] Weighted Average Options Outstanding [Line Items] Weighted Average Options Outstanding Total Lease Receivable Finance lease receivables Other comprehensive income/(loss): Other comprehensive income [abstract] Operating expenses: Operating Expenses [Abstract] Operating Expenses Property and equipment, net Balance at beginning of period Balance at end of period Fixed assets Property, plant and equipment Non-cancellable contractual commitments Contractual capital commitments Issuance of preferred shares of subsidiaries Proceeds from issue of preference shares Trade and other payables Trade and other payables [Member] Trade and other payables Schedule of Trade And Other Payables Schedule of Trade And Other Payables [Text Block] Schedule of Trade And Other Payables The Sync Project Sync [Member] The Sync Project [Member] The Sync Project Share capital [member] Share capital [member] Other financial assets Restricted cash Restricted cash and cash equivalents Total comprehensive income/(loss) for the year Total comprehensive income/(loss) for the year Comprehensive income Comprehensive income Disclosure of Share-based Payment Expense Table Share-based Payment Expense Table [Text Block] Share-based Payment Expense Table Operating Loss Carryforwards, Expiration Periods [Axis] Operating Loss Carryforwards, Expiration Periods [Axis] Operating Loss Carryforwards, Expiration Periods Vesting of restricted stock units Vesting of restricted stock units Vesting of restricted stock units Finance costs, net Adjustments for finance costs Disclosure of quantitative information about right-of-use assets [table] Disclosure of quantitative information about right-of-use assets [table] Accounting Policies - Property and Equipment [Table] Accounting Policies - Property and Equipment [Table] Accounting Policies - Property and Equipment [Table] Sale of asset [Table] Sale of asset [Table] Sale of asset [Table] Revenue [Table] Revenue [Table] Revenue Share-based payment arrangements [member] Share-based payment arrangements [member] Entrega, Inc. (indirectly held through Enlight) Entrega [Member] Entrega [Member] Entrega Leases - Future Payments [Table] Leases - Future Payments [Table] Leases - Future Payments [Table] US treasuries [member] Loans to government [member] Vedanta Biosciences Securities Corp. (indirectly held through Vedanta) Vedanta Biosciences Securities Corp [Member] Vedanta Biosciences Securities Corp Share-Based Payment Arrangements [Abstract] Share-Based Payment Arrangements [Abstract] Disclosure of Payroll Costs Disclosure of Payroll Costs [Text Block] Disclosure of Payroll Costs Lease receivable – long-term Long-term Portion of Lease Receivable Non-current finance lease receivables Diluted earnings/(loss) per share Diluted earnings (loss) per share Changes in operating assets and liabilities: Changes in operating assets and liabilities [Abstract] Changes in operating assets and liabilities Remaining Performance Obligation Performance obligations [axis] Total current assets Current assets Current assets Weighted Average number of ordinary shares [Line Items] Weighted Average number of ordinary shares [Line Items] Weighted Average number of ordinary shares Timing of contract revenue recognition Timing of transfer of goods or services [axis] New Standards and Interpretations Not Yet Adopted Disclosure of expected impact of initial application of new standards or interpretations [text block] Summary Of investments held at fair value Summary Of investments held at fair value [Text Block] Summary Of investments held at fair value Notes Payable [Table] Notes Payable [Table] Notes Payable Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] MASSACHUSETTS MASSACHUSETTS City Area Code City Area Code Neither past due nor impaired [Abstract] Neither past due nor impaired [Abstract] Neither past due nor impaired Basis of Presentation Disclosure of basis of preparation of financial statements [text block] Document Period End Date Document Period End Date Segment Information Disclosure of entity's operating segments [text block] Cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Cash and cash equivalents Undiscounted finance lease payments to be received Undiscounted finance lease payments to be received Cash flows from investing activities: Cash flows from (used in) investing activities [abstract] Other Other Other Share approved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Shares Approved For Issuance Share-based Compensation Arrangement by Share-based Payment Award, Shares Approved For Issuance Weighted average remaining contractual life of outstanding share options Weighted average remaining contractual life of outstanding share options Disclosure of Weighted Average Exercise Prices for Options Forfeited Disclosure of Weighted Average Exercise Prices for Options Forfeited [Text Block] Disclosure of Weighted Average Exercise Prices for Options Forfeited Value at Issuance Warrant Issuance Value at Issuance Value at Issuance Investments held at fair value Disclosure Of Investments held at fair value [Text Block] Disclosure Of Investments held at fair value Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of Weighted Average Exercise Prices for Options Granted Disclosure of Weighted Average Exercise Prices for Options Granted [Text Block] Disclosure of Weighted Average Exercise Prices for Options Granted Foreign currency translation differences Foreign currency exchange Gains (losses) on exchange differences on translation, before tax Contract revenue Milestone Payment Revenue from contracts with customers Net investment in the lease Net investment in finance lease Total Auditor's remuneration Deconsolidation of subsidiary Increase (decrease) through disposal of subsidiary, equity Preferred shares Subsidiary Preferred Shares Beginning balance Ending balance Preferred Share Liability Preferred Share Liability Research and development expenses Research and development expenses Research and development expense Cover [Abstract] Eli Lilly and Company Eli Lilly and Company [Member] Eli Lilly and Company Disclosure of interests in Subsidiaries [Table] Disclosure of interests in Subsidiaries [Table] Disclosure of interests in Subsidiaries [Table] Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items] Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items] Directors and Senior Managers Shareholdings and Share Incentive awards Oxford Finance LLC Oxford Finance LLC [Member] Oxford Finance LLC Disclosure of financial assets [abstract] Loans Long-term loan Loans [Member] Loans Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table] Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table] Alivio Therapeutics, Inc. Alivio [Member] Alivio [Member] Alivio Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Computer equipment and software Computer equipment [member] Range [axis] Range [axis] 2025 Four to five years Later than four years and not later than five years [member] Salaries and wages Wages and salaries Federal tax change Tax rate effect from change in tax rate Auditors Remuneration [Table] Auditors Remuneration [Table] Auditors Remuneration Accrued expenses Accruals classified as current Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] Repayment of long-term debt Repayments of non-current borrowings Earnings Category [Member] Earnings Category [Member] Earnings Category Supplemental disclosure of cash paid for income taxes: Supplemental disclosure of cash paid for incomes taxes [Abstract] Supplemental disclosure of cash paid for incomes taxes BMEB Services LLC BMEB Services LLC [Member] BMEB Services LLC Effect of exchange rates on cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Disclosure of auditors' remuneration Disclosure of auditors' remuneration [text block] Total operating expense Total operating expense Operating expense Minimum Minimum [Member] Earnings/(loss) per share: Earnings per share [abstract] Knode Inc. (indirectly held through Enlight) Knode Knode [Member] Knode Akili [Member] Akili [Member] Akili Accounting policies, changes in accounting estimates and errors [Abstract] Accounting Policies [Abstract] Accounting Policies Issuance of placing shares Issuance of new preferred shares Issue of equity Intangible Assets Description of accounting policy for intangible assets other than goodwill [text block] Other temporary differences Other temporary differences Other temporary differences Dr Joseph Bolen Dr Joseph Bolen [Member] Dr Joseph Bolen Total Contract duration [member] 3.00 to 4.00 Exercise Price Range Four [Member] Exercise Price Range Four [Member] Entity Interactive Data Current Entity Interactive Data Current UNITED STATES UNITED STATES Purchase of intangible asset and investment held at fair value in consideration for issuance of warrant liability and assumption of other long and short-term liabilities purchase of intangible asset and investment in consideration for issuance of warrant and other liability purchase of intangible asset and investment in consideration for issuance of warrant and other liability Financial Assets Description of accounting policy for financial assets [text block] Financial Instruments Disclosure of financial instruments [text block] Statement of cash flows [abstract] Short-term investments Short-term Investments Short-term Investments Receipt of payment of sublease Receipt of payment of sublease Receipt of payment of sublease Deferred tax liabilities [Member] Deferred tax liabilities [Member] Deferred tax liabilities Share of associate loss allocated to long-term interest (please refer to Note 6) Share of associate loss allocated to long-term interest Share of associate loss allocated to long-term interest Share of associate loss allocated to long-term interest Share of associate loss allocated to long-term interest Disclosure of credit risk Disclosure of credit risk [text block] Disclosure of detailed information about borrowings [abstract] Disclosure of detailed information about borrowings [abstract] Financial Assets At Fair Value Through Profit Or Loss after allocation to long-term interest Financial Assets At Fair Value Through Profit Or Loss after allocation to long-term interest Financial Assets At Fair Value Through Profit Or Loss after allocation to long-term interest Ownership Interest Ownership Interest Ownership Interest Expected volatility Expected volatility, share options granted Depreciation Depreciation, property, plant and equipment Earnings/(Loss) attributable to owners of the Company [Table] Earnings/(Loss) attributable to owners of the Company [Table] Earnings/(Loss) attributable to owners of the Company Items that are or may be reclassified as profit or loss Items that are or may be reclassified as profit or loss [Abstract] Items that are or may be reclassified as profit or loss Taxation Disclosure of income tax [text block] Effect of dilutive shares (please refer to Note 8) Dilutive effect of share options on number of ordinary shares Issuance of note receivable Issuance of note receivable Issuance of note receivable Research credits Research credits Research credits Changes in the value of subsidiary preferred shares [Abstract] Changes in the value of subsidiary preferred shares [Abstract] Changes in the value of subsidiary preferred shares Related party transactions [Line Items] Related party transactions [Line Items] Related party transactions Proceeds from issue of convertible notes Proceeds from issue of convertible notes Proceeds from issue of convertible notes Gain on deconsolidation [Table] Gain on deconsolidation [Table] Gain on deconsolidation Sale of Assets Sale of Assets [Text Block] Sale of Assets Ms Dapne Zohar Ms Dapne Zohar [Member] Ms Dapne Zohar Other Increase (decrease) through other changes, equity Deferred Tax Assets and Liabilities [Table] Deferred Tax Assets and Liabilities [Table] Deferred Tax Assets and Liabilities [Table] Capital loss carryovers Capital loss carryovers Capital loss carryovers Proportion of voting rights held in associate Proportion of voting rights held in associate Unobservable inputs [member] Unobservable inputs [member] Transferred over time Goods or services transferred over time [member] Proceeds from the issuance of shares and subsidiary preferred shares Proceeds from issuing shares Accounting Policies Disclosure of significant accounting policies [text block] Document Transition Report Document Transition Report Dr John LaMattina Dr John LaMattina [Member] Dr John LaMattina Income/(loss) from continuing operations (100%) Profit (loss) from continuing operations Financial assets at fair value through profit or loss, category [member] Financial assets at fair value through profit or loss, category [member] Dr Eric Elenko Dr Eric Elenko [Member] Dr Eric Elenko Timing of transfer of goods or services [member] Timing of transfer of goods or services [member] Merger reserve [member] Merger reserve [member] Tal Merger Agreement Disclosure of Merger Agreement [Text Block] Disclosure of Merger Agreement Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Total parent equity [member] Equity attributable to owners of parent [member] Federal [Member] Federal [Member] Federal Dr George Farmer Dr George Farmer [Member] Dr George Farmer Proportion of ownership interest in investee Proportion of ownership interest in investee Proportion of ownership interest in investee Entity File Number Entity File Number Interest Interest On Undiscounted Lease payments Interest On Undiscounted Lease payments Follica, Incorporated Follica [Member] Follica [Member] Follica Total Key management personnel compensation Contributed By - Types [Axis] Contributed By - Types [Axis] Contributed By - Types Equity Equity [abstract] Convertible debt, instruments, converted to equity Convertible Debt, Instruments, Converted To Equity Convertible Debt, Instruments, Converted To Equity Share-based Payments Disclosure of share-based payment arrangements [text block] Tal Merger Agreement [Table] Tal Merger Agreement [Table] Tal Merger Agreement [Table] Performance based Stock option awards [Member] Performance based Stock option awards [Member] Performance based Stock option awards Disclosure of financial assets [table] Disclosure of financial assets [table] Conversion of debt to equity Adjustment for conversion of debt to equity Adjustment for conversion of debt to equity Options exercisable (in shares) Number of options Number of share options exercisable in share-based payment arrangement Proceeds from sale of property and equipment Proceeds from sales of property, plant and equipment, classified as investing activities Series 2 Growth financing Series 2 Growth financing [Member] Series 2 Growth financing Investment upon initial public offering Investment upon initial public offering Investment upon initial public offering Parent Company And Other Parent Company And Other [Member] Parent Company And Other Preferred share transations Preferred share transations [Member] Preferred share transations Grant Income Description of accounting policy for government grants [text block] Grant revenue Income from government grants Document Annual Report Document Annual Report Operating tax losses Current tax assets, current Taxation [Abstract] Taxation [Abstract] Risks [member] Risks [member] Share issued, price per share Share issued, price per share Share issued, price per share Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [table] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [table] Income taxes paid Income taxes paid (refund), classified as operating activities Additional number of shares authorized to purchase Additional number of shares authorized to purchase Additional number of shares authorized to purchase Beginning balance Ending balance Financial liabilities Financial liabilities Audit-related assurance services Audit related assurance services Audit related assurance services Subsidiary warrant liability Warrants [Member] Subsidiary warrant liability [Member] Subsidiary warrant liability Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [text block] Sensitivity Range Percentage of reasonably possible increase in unobservable input, liabilities Exercise price Exercise price Exercise price Earnings/(Loss) attributable to owners of the Company [Line Items] Earnings/(Loss) attributable to owners of the Company [Line Items] Earnings/(Loss) attributable to owners of the Company Settlement of restricted stock units Increase decrease through settlement of restricted stock units Increase decrease through settlement of restricted stock units Number of shares issued by investee Number of shares issued by investee Number of shares issued by investee Categories of financial assets [axis] Categories of financial assets [axis] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items] R&D and orphan drug tax credits Research And Development and orphan drug tax credits Research And Development and orphan drug tax credits Business Or Sourcing Company [Axis] Business Or Sourcing Company [Axis] Business Or Sourcing Company Payments in respect of developmental milestones, dependent on events outside control of company, but reasonably possible to occur Estimated financial effect of contingent liabilities Outstanding at beginning of period Outstanding at end of period Number of share options Number of share options outstanding in share-based payment arrangement Cash flows from financing activities: Cash flows from (used in) financing activities [abstract] Trade and Other Payables Disclosure of trade and other payables [text block] Purchase of associate preferred shares held at fair value Cash purchase of preferred shares Purchase of investments other than investments accounted for using equity method Purchase of investments other than investments accounted for using equity method Disclosure of deferred taxes Disclosure of deferred taxes [text block] Disclosure of Weighted Average Exercise Prices for Options Exercisable Disclosure of Weighted Average Exercise Prices for Options Exercisable [Text Block] Disclosure of Weighted Average Exercise Prices for Options Exercisable Number of shares on conversion from notes Number of shares on conversion from notes Number of shares on conversion from notes Subsidiaries with material non-controlling interests [member] Subsidiaries with material non-controlling interests [member] Categories of related parties [axis] Categories of related parties [axis] Segments [member] Segments [member] Weighted Average Options exercisable [Line Items] Weighted Average Options exercisable [Line Items] Weighted Average Options exercisable Group's share in income/(loss) from continuing operations Share of profit (loss) from continuing operations of associates and joint ventures accounted for using equity method Contributed By [Member] Contributed By [Member] Contributed By Accumulated depreciation and impairment loss Accumulated depreciation, amortisation and impairment [member] Investments held at fair value [Abstract] Investments held at fair value [Abstract] Tal Medical, Inc. Tal Tal [Member] Tal Internal Internal [Member] Internal Entity Ex Transition Period Entity Ex Transition Period Grant date fair value Weighted average fair value at measurement date, share options granted Total Subsidiary Types [Member] Total Subsidiary Types [Member] Total Subsidiary Types Estimated time to exit Estimated time to exit, measurement input [Member] Estimated time to exit, measurement input Number of shares issued and fully paid Number of shares issued and fully paid Share-based Payments Description of accounting policy for share-based payment transactions [text block] Other financial assets Adjustments for decrease (increase) in other assets Investments in associates accounted for using equity method Investments in associates accounted for using equity method Disaggregation of Revenue - Customers over 10% of revenue [Table] Disaggregation of Revenue - Customers over 10% of revenue [Table] Disaggregation of Revenue - Customers over 10% of revenue Property, plant and equipment [member] Property, plant and equipment [member] Borrowings, interest rate Borrowings, interest rate Roche Holding AG Roche Holding AG [Member] Roche Holding AG Granted (in shares) Number of other equity instruments granted in share-based payment arrangement Sonde Health, Inc. Sonde [Member] Sonde [Member] Sonde Lease Liabilities [Table] Lease Liabilities [Table] Lease Liabilities [Table] Conversion of convertible notes Conversion Conversion Conversion Endra Holdings, LLC (held indirectly through Enlight) Endra Holdings LLC [Member] Endra Holdings LLC Proceeds from maturity of short-term investments Proceeds from sales or maturity of financial instruments, classified as investing activities Nontrading holding companies Nontrading holding companies [Abstract] Nontrading holding companies Purchase of property and equipment Purchase of property, plant and equipment, classified as investing activities Directors and Senior Managers Shareholdings and Share Incentive awards [Abstract] Directors and Senior Managers Shareholdings and Share Incentive awards [Abstract] Directors and Senior Managers Shareholdings and Share Incentive awards Non-controlling Interest Disclosure of non-controlling interests [text block] Basis of Measurement Explanation of measurement bases used in preparing financial statements [text block] Current Fiscal Year End Date Current Fiscal Year End Date Unused Federal orphan drug tax credits Unused Federal orphan drug tax credits Unused Federal orphan drug tax credits Issued Share capital acquired Issued Share capital acquired Issued Share capital acquired Voting percentage through the holdings Proportion of voting rights held in subsidiary Tax reform - foreign earnings repatriation Tax rate effect of foreign tax rates Total other financial assets Other financial assets Directors’ and Senior Managers’ Shareholdings and Share Incentive Awards Disclosure Of Information About Shareholdings of Key Management Personnel Explanatory [Text Block] Disclosure Of Information About Shareholdings of Key Management Personnel Explanatory Income – DCF & OPM allocation Income approach [member] Cash paid for income taxes Income taxes paid (refund) Disclosure of operating segments [line items] Disclosure of operating segments [line items] Subsidiary Preferred Shares Balances [Table] Subsidiary Preferred Shares Balances [Table] Subsidiary Preferred Shares Balances [Table] Deconsolidation adjustments Deconsolidation adjustments Deconsolidation adjustments Tal Merger Agreement [Line Items] Tal Merger Agreement [Line Items] Tal Merger Agreement Subsidiary note conversion and changes in NCI ownership interest Subsidiary note conversion and changes in NCI ownership interest Subsidiary note conversion and changes in NCI ownership interest Merger reserve Merger reserve Net loan proceeds Borrowings, Net loan proceeds Borrowings, Net loan proceeds Sensitivity Range Percentage of reasonably possible decrease in unobservable input, liabilities Group's share of total comprehensive income/(loss) Share of total comprehensive income of associates and joint ventures accounted for using equity method Leasehold improvements Leasehold improvements [member] Senior Managers [Abstract] Senior Managers [Abstract] Senior Managers Adjustment for initial application of IFRS 9 Adjustment for initial application of IFRS 9 Adjustment for initial application of IFRS 9 Basic earnings/(loss) per share Basic earnings (loss) per share Executive Compensation Rate of executive compensation, reconciliation of effective tax rate Rate of executive compensation, reconciliation of effective tax rate Deconsolidation of subsidiary Decrease through loss of control of subsidiary, intangible assets other than goodwill Gain on deconsolidation Gains (losses) recognised when control of subsidiary is lost Increase (decrease) in fair value measurement, assets Increase (decrease) in fair value measurement, assets Measurement [axis] Measurement [axis] Weighted average exercise price of, options exercisable (in GBP per share) Weighted average exercise price Weighted average exercise price of share options exercisable in share-based payment arrangement Subsidiary Subsidiary [Abstract] Subsidiary Comprehensive income/(loss) attributable to: Total comprehensive income/(loss) attributable to: Comprehensive income attributable to [abstract] Current financial liabilities Current financial liabilities Unamortized loan discount and issuance costs Borrowings, Discount [Member] Borrowings, Discount Greater than 1 Year Contract Duration Greater Than One Year [Member] Contract Duration Greater Than One Year Subsidiary Plans [Line Items] Subsidiary Plans [Line Items] Subsidiary Plans Sensitivity Range Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Period Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Period Subsidiary Notes Payable Disclosure of Subsidiary Notes Payable [Text Block] Disclosure of Subsidiary Notes Payable Investment in Associates [Abstract] Investment in Associates [Abstract] Investment in Associates [Abstract] Measurement Input, Weighted Term To Exit Measurement Input, Weighted Term To Exit [Member] Measurement Input, Weighted Term To Exit Capital And Financial Risk Management [Line Items] Capital And Financial Risk Management [Line Items] Capital And Financial Risk Management Disclosure of significant unobservable inputs used in fair value measurement of assets [abstract] Disclosure of significant unobservable inputs used in fair value measurement of assets [abstract] Share capital Issued capital Issuance of warrants in subsidiary Issuance of warrants Issuance of warrants Expected dividend yield Expected dividend yield, measurement input [Member] Expected dividend yield, measurement input Subsidiaries [axis] Subsidiaries [axis] Contract Balances [Table] Contract Balances [Table] Contract Balances [Table] Ranges of exercise prices for outstanding share options [member] Ranges of exercise prices for outstanding share options [member] Non-current liabilities Non-current liabilities [abstract] Subsidiary Types [Axis] Subsidiary Types [Axis] Subsidiary Types Weighted average grant date fair value, RSU granted (in GBP per share) Weighted average grant date fair value of other equity instruments granted in share-based payment arrangement Weighted average grant date fair value of other equity instruments granted in share-based payment arrangement Unobservable inputs [axis] Unobservable inputs [axis] Financial Liabilities Description of accounting policy for financial liabilities [text block] Finance income/(costs) – IAS 39 fair value accounting Finance income/(costs) - IAS 39 fair value accounting Finance income/(costs) - IAS 39 fair value accounting Recognised Income Tax Expense [Abstract] Recognised Income Tax Expense [Abstract] Recognised Income Tax Expense Amortization Amortisation, intangible assets other than goodwill Terminal value growth rate Terminal value growth rate, measurement input [Member] Terminal value growth rate, measurement input 2021 Less than one year Not later than one year [member] No Trading Symbol Flag No Trading Symbol Flag Transferred at a point in time – Licensing Income Goods or services transferred at point in time [member] Equity attributable to the owners of the Company Equity attributable to owners of parent Equity attributable to owners of parent Performance obligations [member] Performance obligations [member] Document and Entity Information [Line Items] Document Information [Line Items] Financial liabilities, at fair value Balance at beginning of period Balance at end of period Financial liabilities Financial liabilities, at fair value Average number of employees Average number of employees Changes in the value of subsidiary preferred shares [Roll Forward] Changes in the value of subsidiary preferred shares [Roll Forward] Changes in the value of subsidiary preferred shares Subsidiary Notes Payable - Loans [Table] Subsidiary Notes Payable - Loans [Table] Subsidiary Notes Payable - Loans [Table] Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Revaluation of deferred tax assets related to share-based awards Decrease (increase) through tax on share-based payment transactions, equity Total equity Equity at beginning of period Equity at end of period Equity Transaction Costs Rate of transaction costs Rate of transaction costs Disclosure of quantitative information about right-of-use assets Disclosure of quantitative information about right-of-use assets [text block] Entity's total for impairment of financial assets [member] Entity's total for impairment of financial assets [member] Mark-to-market investment in subsidiary Rate of Mark to Market investment in subsidiary Rate of Mark to Market investment in subsidiary Carrying Amount Carrying amount [member] Disclosure of range of exercise prices of outstanding share options Disclosure of range of exercise prices of outstanding share options [text block] Accounts receivable Adjustments for decrease (increase) in trade and other receivables Intangible assets, net Balance at beginning of period Balance at end of period Intangible assets other than goodwill Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Total current income tax expense/(benefit) Current tax expense (income) Non controlling interests and options issued to third parties Non controlling interests and options issued to third parties Non controlling interests and options issued to third parties Disclosure of Significant unobservable Inputs - Investments at Fair Value, Assets Financial Instruments, Significant unobservable Inputs - Investments at Fair Value, Assets [Text Block] Financial Instruments, Significant unobservable Inputs - Investments at Fair Value, Assets Preferred share warrants Preferred share warrants [Member] Preferred share warrants Notes Payable [Line Items] Notes Payable [Line Items] Notes Payable Local Phone Number Local Phone Number Purchases of short-term investments Purchase of financial instruments, classified as investing activities Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Weighted Average Significant unobservable input, assets Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Subsidiary Plans [Abstract] Subsidiary Plans [Abstract] Subsidiary Plans Statement of changes in equity [abstract] Address Type [Domain] Address Type [Domain] Deconsolidation adjustments Rate of deconsolidation adjustments Rate of deconsolidation adjustments Interest Expense Interest expense, reconciliation of effective tax rate Interest expense, reconciliation of effective tax rate Trade and other receivables [member] Trade receivables [member] Earnings/(loss) per share Earnings/(loss) per share [Abstract] Earnings/(loss) per share Total Share-based Payments Expense Category [Member] Total Share-based Payments Expense Category [Member] Total Share-based Payments Expense Category Probability Weighted Expected Return Method Probability Weighted Expected Return Method [Member] Probability Weighted Expected Return Method Time to Liquidity Time to Liquidity [Member] Time to Liquidity Equity Disclosure of Equity [Text Block] Disclosure of Equity Short-term and Long-term of lease receivables [Table] Short-term and Long-term of lease receivables [Table] Short-term and Long-term of lease receivables [Table] Performance Share Plan [Line Items] Performance Share Plan [Line Items] Performance Share Plan Leases Description of accounting policy for leases [text block] Summary of Financial information of Gelesis Summary of Financial information of Gelesis [Text Block] Summary of Financial information of Gelesis Reclassification of investment at loss of significant influence Reclassification of investment at loss of significant influence Reclassification of investment at loss of significant influence Share of net income/(loss) of associates accounted for using the equity method Share of associate loss allocated to long-term interest (please refer to Note 6) Share of profit (loss) of associates and joint ventures accounted for using equity method Property, plant and equipment [abstract] Additions Additions Lease Liabilities Additions Lease Liabilities Going Concern Disclosure of going concern [text block] Unused tax credits for which no deferred tax asset recognised Unused tax credits for which no deferred tax asset recognised Right of use asset, net Balance at beginning of period Balance at end of period ROU asset Right-of-use assets Vesting of restricted stock units (RSU) Increase Decrease through vesting of RSU Increase Decrease through vesting of RSU Buyback of shares Payments to acquire or redeem entity's shares Finance income [Abstract] Finance income [Abstract] Finance income Adjustments Adjustments, lease liabilities Adjustments, lease liabilities Finance income Total Finance income Finance income Summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations Schedule of summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations [Text Block] Schedule of summary of aggregation of subsidiaries with material non-controlling interests before intra-group eliminations Furniture and fixtures Fixtures and fittings [member] Net assets/(liabilities) Net assets/(liabilities) Assets (liabilities) Stock Incentive Plan [Member] Stock Incentive Plan [Member] Stock Incentive Plan Other reserves [member] Other reserves [member] Financial assets, category [member] Financial assets, category [member] Income tax payable Trade payables, income tax payable Trade payables, income tax payable Disclosure of performance obligations [line items] Disclosure of performance obligations [line items] Boehringer Ingelheim International GMBH Boehringer Ingelheim International GMBH [Member] Boehringer Ingelheim International GMBH Other income/(expense): Other income/(expense) [Abstract] Other income/(expense) Document Registration Statement Document Registration Statement Financial Instruments - Fair value Measurement and Classification [Table] Financial Instruments - Fair value Measurement and Classification [Table] Financial Instruments - Fair value Measurement and Classification [Table] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [table] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [table] Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items] Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items] Entity's total for related parties [member] Entity's total for related parties [member] Finance Cost Net [Abstract] Finance Cost Net [Abstract] Interest rate types [member] Interest rate types [member] More than five years Later than five years [member] Disclosure of Fair Value Measurement and Classification Disclosure of fair value measurement [text block] Deferred tax liability Deferred tax liabilities Deferred tax liabilities Budgeted Costs to complete [Table] Budgeted Costs to complete [Table] Budgeted Costs to complete [Table] Other current financial liabilities Other current financial liabilities